Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel mouse model for checkpoint inhibitor-induced adverse events.

PloS one - 1 Jan 2021

Adam Kieran, Iuga Alina, Tocheva Anna S, Mor Adam

Abstract excerpt

Immune checkpoint inhibitors have demonstrated significant efficacy in the treatment of a variety of cancers, however their therapeutic potential is limited by abstruse immune related adverse events. Currently, no robust animal model exists of checkpoint inhibitor-induced adverse events. Establishing such a model will improve our mechanistic understanding of this process, which in turn will inform design of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Inflammatory Agents
Share to Antibodies, Monoclonal
Share to CTLA-4 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Models, Animal

Share to Immune Checkpoint Inhibitors

Share to Leukocytes

Share to Organ Specificity

Share to Programmed Cell Death 1 Receptor

Source

Open in PubMed Open full text

Identifiers

PMID: 33571254
DOI: 10.1371/journal.pone.0246168
PMCID: PMC7877613

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel mouse model for checkpoint inhibitor-induced adverse events.PMID 33571254Read ↗

Adverse events induced by immune checkpoint inhibitors.Semantic proximity Read ↗

Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition TherapySemantic proximity Read ↗

Research progress on mechanisms and predictive biomarkers for immune-related adverse eventsSemantic proximity Read ↗

Trials, Tribulations, and Trends in Tumor Modeling in MiceSemantic proximity Read ↗

Understanding the pathogenesis of immune checkpoint inhibitor-induced hepatitisSemantic proximity Read ↗

Anti-PD-1 exacerbates bleomycin-induced lung injury in mice via Caspase-3/GSDME-mediated pyroptosisSemantic proximity Read ↗

CSF-1R–Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after ChemotherapySemantic proximity Read ↗

Inhibition of the IL-17A axis Protects against Immune-related Adverse Events while Supporting Checkpoint Inhibitor Anti-tumor EfficacySemantic proximity Read ↗

Inhibition of the IL-17A axis Protects against Immune-related Adverse Events while Supporting Checkpoint Inhibitor Anti-tumor EfficacySemantic proximity Read ↗

Nephrotoxicity of Immune Checkpoint Inhibitors in Mice with a Human Immune SystemSemantic proximity Read ↗

Genetically engineered mouse models of cancer reveal new insights about the antitumor immune responseSemantic proximity Read ↗

Novel mouse model for carcinoembryonic antigen-based therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.